Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450108 | 0.86 | DCUN1D1 (0.46) | NR1H2NR1H3DCUN1D1SMN1; SMN2NPC1 | |
| SCHEMBL6448860 | 0.85 | SMN1; SMN2 (0.53) | NR1H2NR1H3DCUN1D1SMN1; SMN2HSD11B1 | |
| SCHEMBL6454714 | 0.85 | ADORA2A (0.53) | NR1H2NR1H3DCUN1D1SMN1; SMN2NPC1 | |
| SCHEMBL6449864 | 0.84 | CYP1A2 (0.39) | SMN1; SMN2TP53ALDH1A1MEN1KMT2A | |
| SCHEMBL6453811 | 0.81 | NR1H2 (0.49) | NR1H2NR1H3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3199930 | 0.80 | L3MBTL1 (0.58) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL6452381 | 0.80 | SMN1; SMN2 (0.52) | NR1H2NR1H3DCUN1D1SMN1; SMN2NPC1 | |
| SCHEMBL6461011 | 0.79 | GRK6 (0.42) | SMN1; SMN2TP53MEN1KMT2AHPGD | |
| SCHEMBL6454617 | 0.79 | JAK2 (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1SLC22A12 | |
| SCHEMBL6453583 | 0.78 | JAK2 (0.58) | NR1H2NR1H3SMN1; SMN2NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | NR1H2 34/4885NR1H3 24/4885DCUN1D1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.